Mogadan (Nitrazepam)

Nitrazepam binds to a specific site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This enhances the inhibitory action of GABA, increasing chloride ion flow into neurons, which leads to reduced neuronal excitability and the therapeutic effects of sedation, anxiolysis, and seizure control.

The appropriate dose of Mogadan is determined by a qualified prescriber based on the individual patient's clinical condition, age, and response to therapy. Dosage regimens are not standardized in public information and should follow the prescribing information provided by the healthcare professional.

Safety data for nitrazepam in pregnancy and lactation are limited. Generally, the drug is avoided during pregnancy and breastfeeding unless the potential benefit outweighs the risk, as it may cross the placenta and be excreted in breast milk, potentially affecting the fetus or infant.

To order Mogadan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mogadan (nitrazepam) shares the core pharmacological profile of benzodiazepines, such as enhancing GABA activity. Compared with shorter‑acting agents like lorazepam, nitrazepam has a longer half‑life, which may provide more sustained sleep support but also a higher potential for next‑day sedation and accumulation in the elderly.

Mogadan should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat. Ensure the container is tightly closed to maintain stability and protect it from accidental ingestion by children.

Mogadan is supplied as an oral tablet and should be taken by mouth with a glass of water. It is usually swallowed whole and not crushed or chewed, unless otherwise directed by a healthcare professional. Administration timing depends on the indication and the prescriber's instructions.

The most serious risks include respiratory depression, especially when combined with other CNS depressants; severe allergic reactions such as rash or angioedema; paradoxical reactions like agitation or aggression; and the potential for dependence, tolerance, and withdrawal seizures if the medication is stopped abruptly.

Mogadan should be avoided in patients with known hypersensitivity to nitrazepam or other benzodiazepines, in individuals with severe respiratory insufficiency, acute narrow‑angle glaucoma, or severe hepatic impairment. Caution is also advised for patients with a history of substance misuse, and it is contraindicated in children unless specifically prescribed.